jounce
therapeutics
announce
third
quarter
financial
results
host
conference
call
friday
november
cambridge
globe
newswire
jounce
therapeutics
nasdaq
jnce
company
focused
discovery
development
novel
cancer
immunotherapies
predictive
biomarkers
today
announced
report
third
quarter
financial
results
provide
corporate
update
market
open
friday
november
jounce
therapeutics
management
team
host
live
conference
call
webcast
et
conference
call
webcast
access
conference
call
please
dial
domestic
international
refer
conference
id
live
webcast
accessed
events
presentations
investors
media
section
company
website
webcast
archived
made
available
replay
company
website
approximately
two
hours
call
available
days
thereafter
jounce
therapeutics
jounce
therapeutics
immunotherapy
company
dedicated
transforming
treatment
cancer
developing
therapies
enable
immune
system
attack
tumors
provide
benefits
patients
approach
jounce
currently
multiple
programs
ongoing
simultaneously
advancing
additional
assets
robust
discovery
engine
based
translational
science
platform
jounce
lead
product
candidate
vopratelimab
monoclonal
antibody
binds
activates
icos
currently
studied
emerge
select
phase
trials
inhibitor
intended
combination
use
select
study
jounce
broader
pipeline
jounce
next
product
candidate
receptor
antagonist
shown
reprogram
tumor
associated
macrophages
state
phase
trial
evaluating
planned
begin
enrollment
fourth
quarter
additionally
jounce
exclusively
licensed
worldwide
rights
monoclonal
antibody
targeting
designed
selectively
deplete
regulatory
cells
tumor
microenvironment
gilead
sciences
information
please
visit
jounce
investor
media
contacts
malin
deon
mdeon
mark
yore
myore
